Search results
Found 7034 matches for
PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.
Sir Andrew Pollard
BSc MBBS PhD (Lond), DIC, MRCP (UK), FHEA, FRCPCH, MA, FMedSci, FRS Sir Andrew Pollard - Ashall Professor of Infection & Immunity
Yama G.Farooq
BCA Computer Application , MSc in Information Technology and Software Engineering Yama G.Farooq - Programming and Data Management Director
James Gilchrist
MBioch, MBBS, MRCPCH, DPhil, PGDip Paediatric Infectious Diseases James Gilchrist - Wellcome Career Development Fellow
